Cymin

Cymin uses

• Recent major changes
• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Drug interactions
• Use in specific populations
• Overdosage
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• How supplied/storage and handling
• Patient counseling information
• Cymin reviews

RECENT MAJOR CHANGES

Contraindications (4.1) 10/2013

Warnings and Precautions (5.1) 10/2013

1 INDICATIONS AND USAGE

Cymin tablets are indicated for the treatment of cyclic heavy menstrual bleeding [see Clinical Studies ( 14 )].

Prior to prescribing Cymin tablets, exclude endometrial pathology that can be associated with heavy menstrual bleeding.

Cymin tablets are an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding. (1)

2 DOSAGE AND ADMINISTRATION

• 1,300 mg three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation (2.1)
• Renal impairment: Dosage adjustment is needed if serum creatinine concentration (Cr) is higher than 1.4 mg/dL (2.2)
  • Cr above 1.4 mg/dL and ≤ 2.8 mg/dL: 1,300 mg (two 650 mg tablets) two times a day (2,600 mg/day) for a maximum of 5 days during menstruation
  • Cr above 2.8 mg/dL and ≤ 5.7 mg/dL: 1,300 mg (two 650 mg tablets) once a day (1,300 mg/day) for a maximum of 5 days during menstruation
  • Cr above 5.7 mg/dL: 650 mg (one 650 mg tablet) once a day (650 mg/day) for a maximum of 5 days during menstruation

2.1 Recommended Dosage

The recommended dose of Cymin tablets for women with normal renal function is two 650 mg tablets taken three times daily (3900 mg/day) for a maximum of 5 days during monthly menstruation. Cymin tablets may be administered without regard to meals. Tablets should be swallowed whole and not chewed or broken apart.

2.2 Renal Impairment

In patients with renal impairment, the plasma concentration of Cymin increased as serum creatinine concentration increased [see Clinical Pharmacology ( 12.3 )]. Dosage adjustment is needed in patients with serum creatinine concentration higher than 1.4 mg/dL (Table 1).

3 DOSAGE FORMS AND STRENGTHS

650 mg tablets

Tablets: 650 mg (3)

4 CONTRAINDICATIONS

• Women who are using combination hormonal contraception
• Women with active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion (4.1)
  

• Hypersensitivity to Cymin (4.2)

4.1 Thromboembolic Risk

Do not prescribe Cymin tablets to women who are

• using combination hormonal contraception
• known to have any of the following conditions:
  • Active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis)
  • A history of thrombosis or thromboembolism, including retinal vein or artery occlusion
  • An intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy)

Venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported with Cymin.

4.2 Hypersensitivity to Cymin

Do not prescribe Cymin tablets to women with known hypersensitivity to Cymin [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )].

5 WARNINGS AND PRECAUTIONS

• Concomitant use of Cymin tablets with Factor IX complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acid may increase the risk of thrombosis. (5.1)
• Visual or ocular adverse effects may occur with Cymin tablets. Immediately discontinue use if visual or ocular symptoms occur. (5.1)
• In case of severe allergic reaction, discontinue Cymin tablets and seek immediate medical attention. (5.2)
• Cerebral edema and cerebral infarction may be caused by use of Cymin tablets in women with subarachnoid hemorrhage. (5.3)
• Ligneous conjunctivitis has been reported in patients taking Cymin. (5.4)

5.1 Thromboembolic Risk

Concomitant Use of Hormonal Contraceptives

Combination hormonal contraceptives are known to increase the risk of venous thromboembolism, as well as arterial thromboses such as stroke and myocardial infarction. Because Cymin tablets are antifibrinolytic, the risk of venous thromboembolism, as well as arterial thromboses such as stroke, may increase further when hormonal contraceptives are administered with Cymin tablets. This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age.

Women using hormonal contraception were excluded from the clinical trials supporting the safety and efficacy of Cymin tablets, and there are no clinical trial data on the risk of thrombotic events with the concomitant use of Cymin tablets with hormonal contraceptives. However, there have been US postmarketing reports of venous and arterial thrombotic events in women who have used Cymin tablets concomitantly with combination hormonal contraceptives. For this reason, concomitant use of Cymin tablets with combination hormonal contraceptives is contraindicated. [see Contraindications (4.1) and Drug Interactions (7.1) ].

Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates

Cymin tablets is not recommended for women taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased [see Drug Interactions (7.3) and Clinical Pharmacology (12.3) ].

All-Trans Retinoic Acid (Oral Tretinoin)

Exercise caution when prescribing Cymin tablets to women with acute promyelocytic leukemia taking all-trans retinoic acid for remission induction because of possible exacerbation of the procoagulant effect of all-trans retinoic acid [see Drug Interactions (7.4) and Clinical Pharmacology (12.3) ].

Ocular Effects

Retinal venous and arterial occlusion has been reported in patients using Cymin. Patients should be instructed to report visual and ocular symptoms promptly. In the event of such symptoms, patients should be instructed to discontinue Cymin tablets immediately and should be referred to an ophthalmologist for a complete ophthalmic evaluation, including dilated retinal examination, to exclude the possibility of retinal venous or arterial occlusion.

5.2 Severe Allergic Reaction

A case of severe allergic reaction to Cymin tablets was reported in the clinical trials, involving a subject who experienced dyspnea, tightening of her throat, and facial flushing that required emergency medical treatment. A case of anaphylactic shock has also been reported in the literature, involving a patient who received an intravenous bolus of Cymin.

5.3 Subarachnoid Hemorrhage

Cerebral edema and cerebral infarction may be caused by use of Cymin tablets in women with subarachnoid hemorrhage.

5.4 Ligneous Conjunctivitis

Ligneous conjunctivitis has been reported in patients taking Cymin. The conjunctivitis resolved following cessation of the drug.

6 ADVERSE REACTIONS

Most common adverse reactions in clinical trials are headache, sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle cramps, migraine, anemia and fatigue. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Short-term Studies

The safety of Cymin tablets in the treatment of heavy menstrual bleeding (HMB) was studied in two randomized, double-blind, placebo-controlled studies [see Clinical Studies ( 14 )]. One study compared the effects of two doses of Cymin tablets (1950 mg and 3900 mg given daily for up to 5 days during each menstrual period) versus placebo over a 3-cycle treatment duration. A total of 304 women were randomized to this study, with 115 receiving at least one dose of 3900 mg/day of Cymin tablets. A second study compared the effects of Cymin tablets (3900 mg/day) versus placebo over a 6-cycle treatment duration. A total of 196 women were randomized to this study, with 117 receiving at least one dose of Cymin tablets. In both studies, subjects were generally healthy women who had menstrual blood loss of ≥ 80 mL.

In these studies, subjects were 18 to 49 years of age with a mean age of approximately 40 years, had cyclic menses every 21 to 35 days, and a BMI of approximately 32 kg/m². On average, subjects had a history of HMB for approximately 10 years and 40% had fibroids as determined by transvaginal ultrasound. Approximately 70% were Caucasian, 25% were Black, and 5% were Asian, Native American, Pacific Islander, or Other. Seven percent (7%) of all subjects were of Hispanic origin. Women using hormonal contraception were excluded from the trials.

The rates of discontinuation due to adverse events during the two clinical trials were comparable between Cymin tablets and placebo. In the 3-cycle study, the rate in the 3900 mg Cymin tablets dose group was 0.8% as compared to 1.4% in the placebo group. In the 6-cycle study, the rate in the Cymin tablets group was 2.4% as compared to 4.1% in the placebo group. Across the studies, the combined exposure to 3900 mg/day Cymin tablets was 947 cycles and the average duration of use was 3.4 days per cycle.

A list of adverse events occurring in ≥ 5% of subjects and more frequently in Cymin tablets treated subjects receiving 3900 mg/day compared to placebo is provided in Table 2.

^a Includes headache and tension headache

^b Nasal and sinus symptoms include nasal, respiratory tract and sinus congestion, sinusitis, acute sinusitis, sinus headache, allergic sinusitis and sinus pain, and multiple allergies and seasonal allergies

^c Abdominal pain includes abdominal tenderness and discomfort

^d Musculoskeletal pain includes musculoskeletal discomfort and myalgia

^e Arthralgia includes joint stiffness and swelling

Long-term Studies

Long-term safety of Cymin tablets was studied in two open-label studies. In one study, subjects with physician-diagnosed heavy menstrual bleeding (not using the alkaline hematin methodology) were treated with 3900 mg/day for up to 5 days during each menstrual period for up to 27 menstrual cycles. A total of 781 subjects were enrolled and 239 completed the study through 27 menstrual cycles. A total of 12.4% of the subjects withdrew due to adverse events. Women using hormonal contraception were excluded from the study. The total exposure in this study to 3900 mg/day Cymin tablets was 10,213 cycles. The average duration of Cymin tablets use was 2.9 days per cycle.

A long-term open-label extension study of subjects from the two short-term efficacy studies was also conducted in which subjects were treated with 3900 mg/day for up to 5 days during each menstrual period for up to 9 menstrual cycles. A total of 288 subjects were enrolled and 196 subjects completed the study through 9 menstrual cycles. A total of 2.1% of the subjects withdrew due to adverse events. The total exposure to 3900 mg/day Cymin tablets in this study was 1,956 cycles. The average duration of Cymin tablets use was 3.5 days per cycle.

The types and severity of adverse events in these two long-term open-label trials were similar to those observed in the double-blind, placebo-controlled studies although the percentage of subjects reporting them was greater in the 27-month study, most likely because of the longer study duration.

A case of severe allergic reaction to Cymin tablets was reported in the extension trial, involving a subject on her fourth cycle of treatment, who experienced dyspnea, tightening of her throat, and facial flushing that required emergency medical treatment.

6.2 Postmarketing Experience

The following adverse reactions have been identified from postmarketing experience with Cymin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Based on US and worldwide postmarketing reports, the following have been reported in patients receiving Cymin for various

Indications:

• Nausea, vomiting, and diarrhea
• Allergic skin reactions
• Anaphylactic shock and anaphylactoid reactions
• Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction); cases have been associated with concomitant use of combination hormonal contraceptives
• Impaired color vision and other visual disturbances
• Dizziness

7 DRUG INTERACTIONS

No drug-drug interaction studies were conducted with Cymin tablets.

Concomitant therapy with tissue plasminogen activators may decrease the efficacy of both Cymin tablets and tissue plasminogen activators.

7.1 Hormonal Contraceptives

Because Cymin tablets are antifibrinolytic, concomitant use of hormonal contraception and Cymin tablets may further exacerbate the increased thrombotic risk associated with combination hormonal contraceptives. For this reason, concomitant use of Cymin tablets with combination hormonal contraceptives is contraindicated [see Contraindications (4) and Warnings and Precautions ( 5.1 )].

7.2 Tissue Plasminogen Activators

Concomitant therapy with tissue plasminogen activators may decrease the efficacy of both Cymin tablets and tissue plasminogen activators. Therefore, exercise caution if a woman taking Cymin tablets therapy requires tissue plasminogen activators.

7.3 Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates

Cymin tablets are not recommended for women taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased [see Warnings and Precautions and Clinical Pharmacology (12.3) ].

7.4 All-Trans Retinoic Acid (Oral Tretinoin)

Exercise caution when prescribing Cymin tablets to women with acute promyelocytic leukemia taking all-trans retinoic acid for remission induction because of possible exacerbation of the procoagulant effect of all-trans retinoic acid [see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.3 )].

8 USE IN SPECIFIC POPULATIONS

• Geriatric Use: Cymin tablets are not indicated for use in postmenopausal women
• Renal impairment: Dosage adjustment is needed. (2.2, 8.6)
• 
  

  Hepatic impairment: No dosage adjustment is needed. (8.7)
  

8.1 Pregnancy(CategoryB)

Cymin tablets are not indicated for use in pregnant women. Reproduction studies have been performed in mice, rats and rabbits and have revealed no evidence of impaired fertility or harm to the fetus due to Cymin. However, Cymin is known to cross the placenta and appears in cord blood at concentrations approximately equal to the maternal concentration. There are no adequate and well-controlled studies in pregnant women [see Nonclinical Toxicology ( 13.1 )].

An embryo-fetal developmental toxicity study in rats and a perinatal developmental toxicity study in rats were conducted using Cymin. No adverse effects were observed in either study at doses up to 4 times the recommended human oral dose of 3900 mg/day based on mg/m² (actual animal dose 1500 mg/kg/day).

8.3 Nursing Mothers

Cymin is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentration. Cymin tablets should be used during lactation only if clearly needed.

8.4 Pediatric Use

Cymin tablets are indicated for women of reproductive age and are not intended for use in premenarcheal girls. Based on a pharmacokinetic study in 20 adolescent females, 12 to 16 years of age, no dose adjustment is needed in the adolescent population [see Clinical Pharmacology ].

8.5 Geriatric Use

Cymin tablets are indicated for women of reproductive age and are not intended for use by postmenopausal women.

8.6 Renal Impairment

The effect of renal impairment on the pharmacokinetics of Cymin tablets has not been studied. Because Cymin is primarily eliminated via the kidneys by glomerular filtration with more than 95% excreted as unchanged in urine, dosage adjustment in patient with renal impairment is needed [see Dosage and Administration and Clinical Pharmacology ( 12.3 )].

8.7 Hepatic Impairment

The effect of hepatic impairment on the pharmacokinetics of Cymin tablets has not been studied. Because only a small fraction of the drug is metabolized, dosage adjustment in patients with hepatic impairment is not needed [see Clinical Pharmacology ( 12.3 )].

10 OVERDOSAGE

There are no known cases of intentional overdose with Cymin tablets and no subjects in the clinical program took more than 2 times the prescribed amount of Cymin tablets in a 24-hour period (>7800 mg/day). However, cases of overdose of Cymin have been reported. Based on these reports, symptoms of overdose may include gastrointestinal (nausea, vomiting, diarrhea); hypotensive (e.g., orthostatic symptoms); thromboembolic (arterial, venous, embolic); visual impairment; mental status changes; myoclonus; or rash. No specific information is available on the treatment of overdose with Cymin tablets. In the event of overdose, employ the usual supportive measures (e.g., clinical monitoring and supportive therapy) as dictated by the patient's clinical status.

11 DESCRIPTION

Cymin tablets are an antifibrinolytic drug. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:

Cymin is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether. The molecular formula is C₈H₁₅N0₂ and the molecular weight is 157.2.

Cymin tablets are provided as white to off-white, oval-shaped, film coated tablets, debossed with “WPI 3720” on one side of the tablet. The active ingredient in each tablet is 650 mg Cymin. The inactive ingredients contained in each tablet are: colloidal silicon dioxide, copovidone, crospovidone, eudragit, glyceryl behenate, lactose monohydrate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and triethyl citrate.

Structural Formula for Cymin

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Cymin is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of Cymin, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure.

The antifibrinolytic effects of Cymin are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for Cymin and 1 with high affinity (K_d = 1.1 µmol/L). The high affinity lysine site of plasminogen is involved in its binding to fibrin. Saturation of the high affinity binding site with Cymin displaces plasminogen from the surface of fibrin. Although plasmin may be formed by conformational changes in plasminogen, binding to and dissolution of the fibrin matrix is inhibited.

12.2 Pharmacodynamics

Cymin, at in vitro concentrations of 25 to 100 M, reduces by 20 to 60% the maximal rate of plasmin lysis of fibrin catalyzed by tissue plasminogen activator (tPA).

Elevated concentrations of endometrial, uterine, and menstrual blood tPA are observed in women with heavy menstrual bleeding (HMB) compared to women with normal menstrual blood loss. The effect of Cymin on lowering endometrial tPA activity and menstrual fluid fibrinolysis is observed in women with HMB receiving Cymin total oral doses of 2 to 3 g/day for 5 days.

In healthy subjects, Cymin at blood concentrations less than 10 mg/mL has no effect on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood. Cymin, however, at blood concentrations of 1 and 10 mg/mL prolongs the thrombin time.

Cardiac Electrophysiology

The effect of Cymin tablets on QT interval was evaluated in a randomized, single-dose, 4-way crossover study in 48 healthy females aged 18 to 49 years. Subjects received (1) Cymin tablets 1300 mg (two 650 mg tablets), (2) Cymin tablets 3900 mg (six 650 mg tablets; three times the recommended single dose), (3) moxifloxacin 400 mg, and (4) placebo. There was no significant increase in the corrected QT interval at any time up to 24 hours after the administration of either dose of Cymin tablets. Moxifloxacin, the active control, was associated with a maximum 14.11 msec mean increase in corrected QT interval (moxifloxacin – placebo) at 3 hours after administration.

12.3 Pharmacokinetics

Absorption

After a single oral administration of two 650 mg tablets of Cymin tablets, the peak plasma concentration occurred at approximately 3 hours (T_max). The absolute bioavailability of Cymin tablets in women aged 18 to 49 is approximately 45%. Following multiple oral doses (two 650 mg tablets three times daily) administration of Cymin tablets for 5 days, the mean C_max increased by approximately 19% and the mean area under the plasma concentration-time curve (AUC) remained unchanged, compared to a single oral dose administration (two 650 mg tablets). Plasma concentrations reached steady state at the 5^th dose of Cymin tablets on Day 2.

The mean plasma pharmacokinetic parameters of Cymin determined in 19 healthy women following a single (two 650 mg tablets) and multiple (two 650 mg tablets three times daily for 5 days) oral dose of Cymin tablets are shown in Table 3.

C_max = maximum concentration

AUC_tldc = area under the drug concentration curve from time 0 to time of last determinable concentration

AUC_inf = area under the drug concentration curve from time 0 to infinity

T_max = time to maximum concentration

t_1/2 = terminal elimination half-life

^a AUC_0-tau (mcg-h/mL) = area under the drug concentration curve from time 0 to 8 hours

^b Data presented as median (range)

Effect of food: Cymin tablets may be administered without regard to meals. A single dose administration (two 650 mg tablets) of Cymin tablets with food increased both C_max and AUC by 7% and 16%, respectively.

Distribution

Cymin is 3% bound to plasma proteins with no apparent binding to albumin. Cymin is distributed with an initial volume of distribution of 0.18 L/kg and steady-state apparent volume of distribution of 0.39 L/kg.

Cymin crosses the placenta. The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood.

Cymin concentration in cerebrospinal fluid is about one tenth of the plasma concentration.

The drug passes into the aqueous humor of the eye achieving a concentration of approximately one tenth of plasma concentrations.

Metabolism

A small fraction of the Cymin is metabolized.

Excretion

Cymin is eliminated by urinary excretion primarily via glomerular filtration with more than 95% of the dose excreted unchanged. Excretion of Cymin is about 90% at 24 hours after intravenous administration of 10 mg/kg. Most elimination post intravenous administration occurred during the first 10 hours, giving an apparent elimination half-life of approximately 2 hours. The mean terminal half-life of Cymin tablets is approximately 11 hours. Plasma clearance of Cymin is 110 to 116 mL/min.

Specific Populations

Pregnancy (Category B)

Cymin tablets are not indicated for use in pregnant women. Cymin is known to cross the placenta and appears in cord blood at concentrations approximately equal to maternal concentration. There are no adequate and well-controlled studies in pregnant women [see Use in Specific Populations ( 8.1 )].

Nursing Mothers

Cymin is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentrations. Cymin tablets should be used during lactation only if clearly needed [see Use in Specific Populations ( 8.3 )].

Pediatric Use

Cymin tablets are indicated for women of reproductive age and are not intended for use in premenarcheal girls. In a randomized, single dose, two-way crossover study of two dose levels (650 mg and 1,300 mg [two 650 mg tablets]), pharmacokinetics of Cymin was evaluated in 20 female adolescents (12 to 16 years of age) with heavy menstrual bleeding. The C_max and AUC values after a single oral dose of 650 mg in the adolescent females were 32 to 36% less than those after a single oral dose of 1,300 mg in the adolescent females. The C_max and AUC values after a single oral dose of 1300 mg in the adolescent females were 20 to 25% less than those in the adult females given the same dose in a separate study. [See Use in Specific Populations (8.4)]

Geriatric Use

Cymin tablets are indicated for women of reproductive age and are not intended for use by postmenopausal women.

Renal Impairment

The effect of renal impairment on the disposition of Cymin tablets has not been evaluated. Urinary excretion following a single intravenous injection of Cymin declines as renal function decreases. Following a single 10 mg/kg intravenous injection of Cymin in 28 patients, the 24-hour urinary fractions of Cymin with serum creatinine concentrations 1.4 to 2.8, 2.8 to 5.7, and greater than 5.7 mg/dL were 51, 39, and 19%, respectively. The 24-hour Cymin plasma concentrations for these patients demonstrated a direct relationship to the degree of renal impairment. Therefore, dose adjustment is needed in patients with renal impairment [see Dosage and Administration (2.2)].

Hepatic Impairment

The effect of hepatic impairment on the disposition of Cymin tablets has not been evaluated. One percent and 0.5 percent of an oral dose are excreted as a dicarboxylic acid and acetylated metabolite, respectively. Because only a small fraction of the drug is metabolized, no dose adjustment is needed in patients with hepatic impairment.

Drug Interactions

No drug-drug interaction studies were conducted with Cymin tablets.

Hormonal Contraceptives

Because Cymin tablets are antifibrinolytic, concomitant use of hormonal contraception and Cymin tablets may further exacerbate the increased thrombotic risk associated with combination hormonal contraceptives. For this reason, concomitant use of Cymin tablets with combination hormonal contraceptives is contraindicated [see Contraindications (4) , Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )].

Factor IX Complex Concentrates or Anti-inhibitor Coagulant Concentrates

Cymin tablets are not recommended in patients taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.3 ) ].

Tissue Plasminogen Activators

Concomitant therapy with tissue plasminogen activators may decrease the efficacy of both Cymin tablets and tissue plasminogen activators. Therefore, exercise caution if a patient taking Cymin tablets therapy requires tissue plasminogen activators [see Drug Interactions ( 7.2 ) ].

All-Trans Retinoic Acid (Oral Tretinoin)

In a study involving 28 patients with acute promyelocytic leukemia who were given either orally administered all-trans retinoic acid plus intravenously administered Cymin, all-trans retinoic acid plus chemotherapy, or all-trans retinoic acid plus Cymin plus chemotherapy, all 4 patients who were given all-trans retinoic acid plus Cymin died, with 3 of the 4 deaths due to thrombotic complications. It appears that the procoagulant effect of all-trans retinoic acid may be exacerbated by concomitant use of Cymin. Therefore, exercise caution when prescribing Cymin tablets to patients with acute promyelocytic leukemia taking all-trans retinoic acid [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.4 )].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies with Cymin in male mice at doses as high as 6 times the recommended human dose of 3900 mg/day showed an increased incidence of leukemia which may have been related to treatment. Female mice were not included in this experiment.

The dose multiple referenced above is based on body surface area. Actual daily dose in mice was up to 5000 mg/kg/day in food.

Hyperplasia of the biliary tract and cholangioma and adenocarcinoma of the intrahepatic biliary system have been reported in one strain of rats after dietary administration of doses exceeding the maximum tolerated dose for 22 months. Hyperplastic, but not neoplastic, lesions were reported at lower doses. Subsequent long-term dietary administration studies in a different strain of rat, each with an exposure level equal to the maximum level employed in the earlier experiment, have failed to show such hyperplastic/neoplastic changes in the liver.

Mutagenesis

Cymin was neither mutagenic nor clastogenic in the in vitro Bacterial Reverse Mutation Assay (Ames test), in vitro chromosome aberration test in Chinese hamster cells, and in in vivo chromosome aberration tests in mice and rats.

Impairment of Fertility

Reproductive studies performed in mice, rats and rabbits have not revealed any evidence of impaired fertility or adverse effects on the fetus due to Cymin.

In a rat embryo-fetal developmental toxicity study, Cymin had no adverse effects on embryo-fetal development when administered during the period of organogenesis (from gestation days 6 through 17) at doses 1, 2 and 4 times the recommended human oral dose of 3900 mg/day. In a perinatal-postnatal study in rats, Cymin had no adverse effects on pup viability, growth or development when administered from gestation day 6 through postnatal day 20 at doses 1, 2 and 4 times the recommended human oral dose of 3900 mg/day.

The dose multiples referenced above are based on body surface area (mg/m²). Actual daily doses in rats were 300, 750 or 1500 mg/kg/day.

13.2 Animal Toxicology and/or Pharmacology

Ocular Effects

In a 9-month toxicology study, dogs were administered Cymin in food at doses of 0, 200, 600, or 1200 mg/kg/day. These doses are approximately 2, 5, and 6 times, respectively, the recommended human oral dose of 3900 mg/day based on AUC. At 6 times the human dose, some dogs developed reversible reddening and gelatinous discharge from the eyes. Ophthalmologic examination revealed reversible changes in the nictitating membrane/conjunctiva. In some female dogs, the presence of inflammatory exudate over the bulbar conjunctival mucosa was observed. Histopathological examinations did not reveal any retinal alteration. No adverse effects were observed at 5 times the human dose.

In other studies, focal areas of retinal degeneration were observed in cats, dogs and rats following oral or intravenous Cymin doses at 6 to 40 times the recommended usual human dose based on mg/m² (actual animal doses between 250 to 1600 mg/kg/day).

14 CLINICAL STUDIES

The efficacy and safety of Cymin tablets in the treatment of heavy menstrual bleeding was demonstrated in one 3-cycle treatment and one 6-cycle treatment, randomized, double-blind, placebo-controlled study [see Adverse Reactions ( 6 .1 )]. In these studies, HMB was defined as an average menstrual blood loss of ≥ 80 mL as assessed by alkaline hematin analysis of collected sanitary products over two baseline menstrual cycles. Subjects were 18 to 49 years of age with a mean age of approximately 40 years, had cyclic menses every 21 to 35 days, and a BMI of approximately 32 kg/m². On average, subjects had an HMB history of approximately 10 years and 40% had fibroids as determined by transvaginal ultrasound. Approximately 70% were Caucasian, 25% were Black, and 5% were Asian, Native American, Pacific Islander, or Other. Seven percent (7%) of all subjects were of Hispanic origin.

In these studies, the primary outcome measure was menstrual blood loss (MBL), measured using the alkaline hematin method. The endpoint was change from baseline in MBL, calculated by subtracting the mean MBL during treatment from the mean pretreatment MBL.

The key secondary outcome measures were based on specific questions concerning limitations in social or leisure activities (LSLA) and limitations in physical activities (LPA). Large stains (soiling beyond the undergarment) were also included as a key secondary outcome measure.

14.1 Three-Cycle Treatment Study

This study compared the effects of two doses of Cymin tablets (1950 mg and 3900 mg given daily for up to 5 days during each menstrual period) versus placebo on MBL over a 3-cycle treatment duration. Of the 294 evaluable subjects, 115 Cymin tablets 1950 mg/day subjects, 112 Cymin tablets 3900 mg/day subjects and 67 placebo subjects took at least one dose of study drug and had post-treatment data available.

Results are shown in Table 4. MBL was statistically significantly reduced in patients treated with 3900 mg/day Cymin tablets compared to placebo. Study success also required achieving a reduction in MBL that was determined to be clinically meaningful to the subjects. The 1950 mg/day Cymin tablets dose did not meet the criteria for success.

* p<0.001 versus placebo

Cymin tablets also statistically significantly reduced limitations on social, leisure, and physical activities in the 3900 mg/day dose group compared to placebo (see Table 5). No statistically significant treatment difference was observed in response rates on the number of large stains.

^a Response categories: 1=not at all limited; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; 5=extremely limited

^b Positive means reflect an improvement from baseline.

^c p-value <0.05 versus placebo

^d Responders are defined as subjects who experienced a reduction from baseline in frequency of large stains.

^e Non-significant difference versus placebo

14.2 Six-Cycle Treatment Study

This study compared the effects of Cymin tablets 3900 mg/day given daily for up to 5 days during each menstrual period versus placebo on MBL over a 6-cycle treatment duration. Of the 187 evaluable subjects, 115 Cymin tablets subjects and 72 placebo subjects took at least one dose of study drug and had post-treatment data available.

Results are shown in Table 6. MBL was statistically significantly reduced in patients treated with 3900 mg/day Cymin tablets compared to placebo. Study success also required achieving a reduction in MBL that was determined to be clinically meaningful to the subjects.

* p<0.001 versus placebo

Limitations on social, leisure, and physical activities were also statistically significantly reduced in the Cymin tablets group compared to placebo (see Table 7). No statistically significant treatment difference was observed in response rates on the number of large stains.

^a Response categories: 1=not at all limited; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; 5=extremely limited

^b Positive means reflect an improvement from baseline

^c p-value <0.05 versus placebo

^d Responders are defined as subjects who experienced a reduction from baseline in frequency of large stains

^e Non-significant difference versus placebo

14.3 MBL Results over Time

The efficacy of Cymin tablets 3900 mg/day over 3 menstrual cycles and over 6 menstrual cycles was demonstrated versus placebo in the double-blind, placebo-controlled efficacy studies (see Figure 1). The change in MBL from baseline was similar across all post-baseline treatment cycles.

Figure 1: MBL Levels over Duration of Therapy

Figure 1 - The efficacy of Cymin tablets 3900 mg/day over 3 menstrual cycles and over 6 menstrual cycles was demonstrated versus placebo in the double-blind, placebo-controlled efficacy studies.

16 HOW SUPPLIED/STORAGE AND HANDLING

Cymin tablets are provided as white to off-white, oval-shaped, film coated tablets. Each tablet is debossed with “WPI 3720” on one side of the tablet and are supplied as:

Storage

Store at 20º to 25º C (68º to 77º F)..

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Patient Information)

Instruct patients that the usual schedule is to take two tablets with liquids, three times a day during menstruation. Patients should be instructed not to exceed 3 doses (6 tablets) in a 24-hour period or to take for more than 5 days in any menstrual cycle.

Inform patients that they should immediately stop Cymin tablets if they notice any eye symptoms or change in their vision. Instruct them to report any such problems promptly to their physician and to follow-up with an ophthalmologist for a complete ophthalmic evaluation, including dilated retinal examination of the retina.

Inform patients that they should stop Cymin tablets and seek immediate medical attention if they notice symptoms of a severe allergic reaction (e.g., shortness of breath or throat tightening).

Instruct patients that common side effects of Cymin tablets include headache, sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle cramps, migraine, anemia and fatigue.

Advise patients to contact their healthcare provider if their heavy menstrual bleeding symptoms persist or worsen.

Remind patients to read the Patient Labeling carefully.

PATIENT INFORMATION

Tranexamic (tran-eks-am-ik) acid tablets

Read the Patient Information that comes with Cymin tablets before you start using the drug and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What are Cymin tablets ?

Cymin tablets are a prescription medicine used to treat your heavy monthly period (menstruation) when your bleeding gets in the way of social, leisure and physical activities. Cymin tablets do not contain any hormones. On average, Cymin tablets have been shown to lower the amount of blood lost during your monthly period by about one-third, but it is not meant to stop your period.

Cymin tablets are taken only during your period and are not meant to treat pre-menstrual symptoms (symptoms that occur before your bleeding starts). Cymin tablets do not affect your fertility and cannot be used as birth control. Cymin tablets do not protect you against diseases that you may get if you have unprotected sex.

Cymin tablets have not been studied in adolescents younger than 18 years of age.

Cymin tablets are not for women who have already gone through menopause (post-menopausal).

Who should not take t ranexamic acid tablets ?

Do not take Cymin tablets if you:

• Are using a form of birth control that contains estrogen and a progestin (like a birth control pill, patch, or vaginal ring). Ask your healthcare provider before taking Cymin tablets if you are not sure if your birth control method contains estrogen and a progestin.
• Currently have a blood clot
• Have ever had a blood clot
• Have been told that you are at risk of having a blood clot
• Are allergic to Cymin tablets or Cymin

What should I tell my healthcare provider before taking t ranexamic acid tablets ?

Before taking Cymin tablets, tell your healthcare provider about all of your medical conditions, including whether:

• You have ever had a blood clot or been told that you are at risk of having a blood clot
• You are using a form of birth control that contains estrogen and a progestin (like a birth control pill, patch, or vaginal ring). Using hormonal birth control along with Cymin tablets may increase your chance of having a serious blood clot, stroke, or heart attack. For this reason, do not use Cymin tablets if you use a form of birth control that contains estrogen and a progestin.
• You are pregnant or think you may be pregnant
• You are breastfeeding or plan to breastfeed. Tranexamic acid can pass into your milk. Talk to your healthcare provider about the best way to feed your baby if you take Cymin tablets.
• The time between the start of your periods is less than 21 days or more than 35 days
• You have any other medical conditions

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Cymin tablets and other medicines can affect each other, causing side effects. Cymin tablets can affect the way other medicines work and other medicines can affect how Cymin tablets work.

Especially tell your healthcare provider if you take:

• Birth control pills or other hormonal birth control
• Medicines used to help your blood form clots
• Medicines used to break up blood clots
• Any medicines to treat leukemia

Ask your healthcare provider if you are not sure if your medicine is one that is described above.

How should I take t ranexamic acid tablets ?

• Take Cymin tablets exactly as your healthcare provider tells you.
• Do not take Cymin tablets until your period has started.
• Do not take Cymin tablets for more than 5 days in a row.
• Do not take Cymin tablets when you do not have your period.
• Once your period has started, take 2 tablets of Cymin tablets three times per day (e.g., in the morning, afternoon, and evening).
• Cymin tablets should be swallowed whole and not chewed or broken apart.
• Cymin tablets may be taken with or without food.
• Do not take more than 6 tablets of Cymin tablets in a day. If you take more than 6 tablets, call your healthcare provider.
• If you miss a dose, take it when you remember, and then take your next dose at least six hours later. Do not take more than two tablets at a time to make up for missed doses.
• If Cymin tablets do not help to lessen bleeding with your periods after 2 cycles or seems to stop working, talk to your healthcare provider.

What are the possible side effects of t ranexamic acid tablets ?

Cymin tablets can cause serious side effects, including:

• Blood clots. You may have a higher risk of having serious blood clots if you take Cymin tablets with:
  • medicines used to help your blood form clots
  • some medicines used to treat leukemia
• Eye changes. Stop taking Cymin tablets and promptly report any eye problems you have while taking Cymin tablets. Your doctor will refer you to an eye doctor who will examine your eyes.
• Allergic reaction. If you have severe shortness of breath and your throat feels tight, stop taking Cymin tablets and get medical care right away.

The most common side effects of Cymin tablets include:

• Headaches
• Sinus and nasal problems
• Back pain
• Pain in your abdomen
• Pain in your muscles or joints
• Anemia
• Fatigue

Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all of the possible side effects of Cymin tablets. For more information, ask your healthcare provider or pharmacist.

If you notice a change in your usual bleeding pattern that worries you, or your heavy bleeding continues, contact your healthcare provider right away. This may be a sign of a more serious condition .

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Actavis at 1-800-272-5525.

How should I store t ranexamic acid tablets ?

Store Cymin tablets at room temperature between 20º to 25º C (68º to 77º F).

Keep t ranexamic acid tablets and all medicines out of the reach of children.

General information about t ranexamic acid tablets

Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information Leaflets. Do not use Cymin tablets for a condition for which it was not prescribed. Do not give Cymin tablets to other people, even if they have the same symptoms that you have. It may harm them.

This patient information leaflet summarizes the most important information about Cymin tablets. If you would like more information about Cymin tablets, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Cymin tablets that is written for healthcare professionals. For more information, go to www.actavis.com or call 1-800-272-5525.

What are the ingredients of Cymin tablets ?

Active ingredient: Cymin

Inactive ingredients: colloidal silicon dioxide, copovidone, crospovidone, eudragit, glyceryl behenate, lactose monohydrate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and triethyl citrate.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Actavis Laboratories FL, Inc.

Fort Lauderdale, FL 33314 USA

Distributed by:

Actavis Pharma, Inc.

Parsippany, NJ 07054 USA

Revised: November 2014 197511-2

NDC 0591-3720-30

Cymin Tablets 650 mg

PHARMACIST: PLEASE DISPENSE IN THIS CHILD-RESISTANT

CONTAINER WITH PATIENT INFORMATION LEAFLET PROVIDED.

Watson 30 Tablets Rx only

NDC 0591-3720-30 Cymin Tablets 650 mg PHARMACIST: PLEASE DISPENSE IN THIS CHILD-RESISTANT CONTAINER WITH PATIENT INFORMATION LEAFLET PROVIDED. Watson 30 Tablets Rx only

Cymin pharmaceutical active ingredients containing related brand and generic drugs:

• Tranexamic Acid

Cymin available forms, composition, doses:

• Tablets; Oral; Tranexamic Acid 250 mg
• Tablets; Oral; Tranexamic Acid 500 mg

Cymin destination | category:

• Human:
• Hemostatics

Cymin Anatomical Therapeutic Chemical codes:

• B02AA02 - Tranexamic Acid

Cymin pharmaceutical companies:

• Wockhardt

References

1. Dailymed."TRANEXAMIC ACID TABLET, FILM COATED [ACTAVIS PHARMA, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."TRANEXAMIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. "tranexamic acid". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Depending on the reaction of the Cymin after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Cymin not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

Visitor reports

Visitor reviews

The information was verified by Dr. Rachana Salvi, MD Pharmacology